Momenta Pharmaceuticals, Inc. (MNTA)

[investorgold2002]

Dr Reddy's cc

interesting
http://www.drreddys.com/investors/pdf/Q1FY12-Transcript.pdf

Another point is that, as you were saying is that you are also putting money on proprietary technology through R&D expenditure and going by the kind of niche product as fonda has. Are you planning or do you have in your pipeline any similar carbohydrates synthesis based products which are pretty complex in nature and your team has done a fantastic job by scaling up. So do you have any product in pipeline or any expectation in say next two years time?


Umang Vohra We have products in our pipeline which are very complicated and require characterization like fonda required and we have got a nice emerging pipeline of that.

It will be from the US side, it will more dictated by the patent expiries and as
of now we don’t have any therapy bias in the portfolio. But from a
complexity perspective you know we would like to increase the proportion of
characterization led new products because that is where our strength lies.


biosimilars

Nitin Agarwal One is on the biosimilars front, you know even in the annual report we
stressed quite a bit upon our capabilities in biosimilars and that being our
medium term growth driver. So beyond the launches that you have done in
India, how do you see the biosimilar road map really playing out for us over
the next 2-3 years?

G. V. Prasad We have started registering the products in markets, which will allow us to
register products on basis of the clinical trials we have done in India and
some marginal additional trials. So that revenue, I think will become

significant by 2014 or so. But the real value unlocking will happen when the
products are launched in the US and European markets. So for these, we have
to do much bigger trials and our plan is to partner with somebody who has
the expertise to do large scale clinical trials as well as detail and market the
product in these geographies. So, in the meanwhile we are progressing the
product and we had EMEA meetings. We have requested a meeting with the
US FDA and the process of registering and doing the clinical trial will
continue, we will not wait for a partner. But we believe that the full potential
of the first few biosimilars from Dr. Reddy’s portfolio will be unlocked only
with a strong partner. So but you know these patents have to expire, we have
to do the trials, we have to file. So they are a little bit away 2015-16 onwards.